These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35072756)

  • 21. Detection of N-desethyl etonitazene in a drug checking sample: Chemical analysis and pharmacological characterization of a recent member of the 2-benzylbenzimidazole "nitazene" class.
    Monti MC; De Vrieze LM; Vandeputte MM; Persson M; Gréen H; Stove CP; Schlotterbeck G
    J Pharm Biomed Anal; 2024 Dec; 251():116453. PubMed ID: 39216307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The
    Tsai MM; Chen L; Baumann MH; Canals M; Javitch JA; Lane JR; Shi L
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible biased analgesic of hydromorphone through the G protein-over β-arrestin-mediated pathway: cAMP, CellKey™, and receptor internalization analyses.
    Manabe S; Miyano K; Fujii Y; Ohshima K; Yoshida Y; Nonaka M; Uzu M; Matsuoka Y; Sato T; Uezono Y; Morimatsu H
    J Pharmacol Sci; 2019 Jun; 140(2):171-177. PubMed ID: 31320243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
    Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
    Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure.
    Åstrand A; Vikingsson S; Jakobsen I; Björn N; Kronstrand R; Gréen H
    Drug Test Anal; 2021 Jan; 13(1):169-174. PubMed ID: 32749741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.
    Cox EH; Kerbusch T; Van der Graaf PH; Danhof M
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1095-103. PubMed ID: 9495871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids.
    De Vrieze LM; Walton SE; Pottie E; Papsun D; Logan BK; Krotulski AJ; Stove CP; Vandeputte MM
    Arch Toxicol; 2024 Sep; 98(9):2999-3018. PubMed ID: 38877156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of "Nitazene" 2-Benzylbenzimidazole Synthetic Opioids.
    Vandeputte MM; Van Uytfanghe K; Layle NK; St Germaine DM; Iula DM; Stove CP
    ACS Chem Neurosci; 2021 Apr; 12(7):1241-1251. PubMed ID: 33759494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats.
    Hashimoto T; Saito Y; Yamada K; Hara N; Kirihara Y; Tsuchiya M
    Anesthesiology; 2006 Sep; 105(3):574-80. PubMed ID: 16931992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-
    Puig S; Barker KE; Szott SR; Kann PT; Morris JS; Gutstein HB
    Mol Pharmacol; 2020 Oct; 98(4):487-496. PubMed ID: 32723769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor.
    Frölich N; Dees C; Paetz C; Ren X; Lohse MJ; Nikolaev VO; Zenk MH
    Biochem Pharmacol; 2011 May; 81(10):1248-54. PubMed ID: 21396918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors.
    Wittmann M; Schaaf T; Peters I; Wirz S; Urban BW; Barann M
    Anesth Analg; 2008 Jul; 107(1):107-12. PubMed ID: 18635474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data.
    Kalvass JC; Olson ER; Cassidy MP; Selley DE; Pollack GM
    J Pharmacol Exp Ther; 2007 Oct; 323(1):346-55. PubMed ID: 17646430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.
    Deventer MH; Persson M; Laus A; Pottie E; Cannaert A; Tocco G; Gréen H; Stove CP
    Arch Toxicol; 2023 May; 97(5):1367-1384. PubMed ID: 36853332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the µ-opioid receptor.
    Xie B; Goldberg A; Shi L
    Comput Struct Biotechnol J; 2022; 20():2309-2321. PubMed ID: 35615021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Structure-Activity Relationship Exploration of Alkyl/Phenylalkyl Piperidine Analogues as Novel Highly Potent and Selective μ Opioid Receptor Agonists.
    Huang H; Li X; Guo W; Zhu C; Qian Y; Shen Q; Xu X; Li W; Wang Y; Fu W
    ACS Chem Neurosci; 2021 Jan; 12(2):285-299. PubMed ID: 32852933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic fentanyl treatments induce the up-regulation of mu opioid receptor mRNA in rat pheochromocytoma cells.
    Yoshikawa M; Nakayama H; Ueno S; Hirano M; Hatanaka H; Furuya H
    Brain Res; 2000 Mar; 859(2):217-23. PubMed ID: 10719067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons.
    Zollner C; Shaqura MA; Bopaiah CP; Mousa S; Stein C; Schafer M
    Mol Pharmacol; 2003 Aug; 64(2):202-10. PubMed ID: 12869624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.